City

Tianjin (1)

Condition

Resectable Biliary Tract Cancer (2)

Overall Status

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Tianjin Medical University Cancer Institute and Hospital (1)

Collaborator

Bristol-Myers Squibb (1)

Intervention

cabrilizumab (1)

cisplatin (1)

durvalumab (1)

gemcitabine (1)

nab-paclitaxel (1)

nivolumab (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

resectable biliary tract cancer

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Resectable Biliary Tract Cancer Trial in Tianjin (Cisplatin, Gemcitabine, Nab-paclitaxel)

Recruiting

Resectable Biliary Tract Cancer

Cisplatin
+3 more

Tianjin, Tianjin, China

Tianjin Cancer Hospital Airport Hospital

Nov 30, 2022

Resectable Biliary Tract Cancer Trial (Nivolumab, Cabrilizumab)

Withdrawn

Resectable Biliary Tract Cancer

(no location specified)

Apr 9, 2020